Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
China
Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin Municipality The Second Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang